NCT05254925COMPLETEDanonymous

Evaluation of Topically Applied Bemotrizinol for Human Phototoxic Potential

Sponsor

Source record

dsm-firmenich Switzerland AG

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

6% Bemotrizinol (BEMT)

Indication / condition

AI-normalized

Phototoxic Response

Intervention

Source record

Sunscreen oil with 6% Bemotrizinol, Sunscreen oil vehicle, Dispersion of 6% BEMT in petrolatum, Petrolatum vehicle

Related intelligence directories

Indication directory: Phototoxic Response Modality directory: small molecule Target directory: 6% Bemotrizinol (BEMT)

Source & freshness

Source record

NCT ID

NCT05254925

Original source

ClinicalTrials.gov

Source last updated

Aug 26, 2022

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT05254925

Title

Evaluation of Topically Applied Bemotrizinol for Human Phototoxic Potential

Sponsor

dsm-firmenich Switzerland AG

Status

COMPLETED

Phase

PHASE2

Condition raw

Phototoxic Response

Condition normalized

Phototoxic Response

Modality raw

Phototoxic Response

Modality normalized

small molecule

Target raw

6% Bemotrizinol (BEMT)

Target normalized

6% Bemotrizinol (BEMT)

Interventions

Sunscreen oil with 6% Bemotrizinol, Sunscreen oil vehicle, Dispersion of 6% BEMT in petrolatum, Petrolatum vehicle

Public preview

Source record

This clinical trial evaluated the phototoxic potential of 6% Bemotrizinol in various formulations compared to vehicle controls. Conducted by dsm-firmenich Switzerland AG, the study aimed to assess safety and efficacy in human subjects, focusing on skin reactions post-UV exposure.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Evaluation of Topically Applied Bemotrizinol for Human Phototoxic Potential

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT05254925

Status

COMPLETED

Phase

PHASE2

Sponsor

dsm-firmenich Switzerland AG

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedAug 26, 2022

Internal syncJun 05, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05254925

Indication

Phototoxic Response

Modality

small molecule

Target

6% Bemotrizinol (BEMT)

Intervention

Sunscreen oil with 6% Bemotrizinol, Sunscreen oil vehicle, Dispersion of 6% BEMT in petrolatum, Petrolatum vehicle

Source record